
Unlearn.AI builds AI-generated digital twins of clinical trial participants — forecasts of how each individual patient's outcomes would evolve — and uses them to sharpen design, interim, and readout decisions in drug development.
| 항목 / 지표 | ![]() | |
|---|---|---|
| 공식 도메인 | delve.ai | unlearn.ai |
| 가격 모델 | 무료+유료 | 가격 문의 |
| 월간 방문 수 | 4.9만 (49,025) | 1.71만 (17,107) |
| 전월 대비 트래픽 변화량 | -2.35천 (-4.6%) | -8.23천 (-32.5%) |
| 주요 시장 및 점유율 | 🇺🇸 미국 (10.9%) | 🇺🇸 미국 (69.4%) |
| 월 직접 방문 수 | 1.97만 | 7.49천 |
| 사용자 평점 | 4.3 | 4.4 |
| 지원 플랫폼 | 웹사이트 | 웹사이트 |
데이터 기반 페르소나, 디지털 트윈, 합성 리서치를 즉시 생성
자사 및 공개 데이터로 고객, 사용자, 오디언스, 직원 페르소나를 구축하고 자동 세분화와 심층 인사이트를 제공합니다.
페르소나를 24시간 대화 가능한 트윈으로 바꿔 인터뷰 일정 없이 아이디어를 검증하고 질문하며 고객 중심 결정을 내립니다.
오디언스의 AI 페르소나에게 설문, 인터뷰, 포커스 그룹, UX 테스트를 실행해 몇 분 만에 확장 가능하고 저렴한 결과를 얻습니다.
페르소나 인사이트에서 도출한 채널별 마케팅·캠페인 추천을 생성하고 데이터 변화에 따라 업데이트합니다.

Unlearn.AI builds AI-generated digital twins of clinical trial participants — forecasts of how each individual patient's outcomes would evolve — and uses them to sharpen design, interim, and readout decisions in drug development.
Model-based forecasts of each participant's clinical outcomes, generated from baseline data already collected, that act as a virtual comparator or as additional information per enrolled patient.
A twin-based covariate adjustment approach that Unlearn describes as EMA-qualified and FDA-supported, used to reduce sample size in randomized controlled trials while maintaining power.
Build and compare design scenarios — endpoints, eligibility criteria, sample size, assumptions — so governance decisions are made with quantified tradeoffs instead of positions.
Pre-specified twin-based analyses added to the statistical analysis plan before unblinding, plus twin-adjusted analysis delivered at interim and at readout.
무료 / 오픈소스정신건강 전문가를 위한 AI 치료 노트와 AI 네이티브 EHR.
AI로 검진 대상자를 찾고 결절마다 위험 점수를 산출
AI, 자동화, 데이터 품질 관리를 하나로 묶은 애자일 MROps 플랫폼


RapidAI is an enterprise clinical AI platform that connects medical imaging to clinical decisions across neurology, cardiac and vascular care, trauma, emergency departments and oncology. Its FDA-cleared algorithms analyze CT, CT angiography, MRI and other scans to detect and quantify conditions such as large vessel occlusion stroke, aneurysms, aortic disease, pulmonary embolism, fractures and critical chest findings, then push the results to the care teams who need them. The Rapid Enterprise platform layers workflow integration, scalable infrastructure, data analytics and third-party partner AI on top of the core models, so health systems can run deep clinical AI across entire service lines rather than isolated point tools.
RapidAI is an enterprise clinical AI platform that connects medical imaging to clinical decisions across neurology, cardiac and vascular care, trauma, emergency departments and oncology. Its FDA-cleared algorithms analyze CT, CT angiography, MRI and other scans to detect and quantify conditions such as large vessel occlusion stroke, aneurysms, aortic disease, pulmonary embolism, fractures and critical chest findings, then push the results to the care teams who need them. The Rapid Enterprise platform layers workflow integration, scalable infrastructure, data analytics and third-party partner AI on top of the core models, so health systems can run deep clinical AI across entire service lines rather than isolated point tools.